



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Multiple sheets used when necessary) SHEET 1 OF 1	Application No.	10/066,500
	Filing Date	February 1, 2002
	First Named Inventor	Avi J. Ashkenazi
	Art Unit	1649
	Examiner	Chernyshev, Olga
	Attorney Docket No.	GNE.3130RIC7

U.S. PATENT DOCUMENTS				
Examiner Initials	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	ALON, et al. "Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity." <i>Nature Medicine</i> . 1(10): 1024-1028 (1995).	
	2	BENJAMIN, et al. "Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal." <i>Proc. Natl. Acad. Sci.</i> 94: 8761-8766 (1997).	
	3	ELLIS, et al. "Synopsis of Angiogenesis Inhibitors in Oncology." <i>Oncology</i> . 16(5), Supplement: 14-22 (2002).	
	4	FERRARA, Napoleone. "The role of vascular endothelial growth factor in pathological angiogenesis." <i>Breast Cancer Research and Treatment</i> . 36: 127-137 (1995).	
	5	FIDLER, et al. "Critical Determinants of Neoplastic Angiogenesis." <i>The Cancer Journal</i> . 6(Suppl. 3): S225-S236 (2000).	
	6	JANKNECHT, et al. "Signal integration at the c-fos promoter." <i>Carcinogenesis</i> . 16(3): 443-450 (1995).	
	7	KIRKPATRICK, Peter. "Bevacizumab." <i>Nature</i> . Nature Reviews/Drug Discover. Nature Publishing Group. S8-S9 (May 2005).	
	8	KOLCH, et al. "Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis." <i>Breast Cancer Research and Treatment</i> . 36: 139-155 (1995).	
	9	NEHLS, et al. "Pericyte involvement in capillary sprouting during angiogenesis in situ." <i>Cell Tissue Res.</i> 270: 469-474 (1992).	
	10	RHODIN, et al. "Capillary growth in the mesentery of normal young rats. Intravital video and electron microscope analyses." <i>J. Submicrosc. Cythol. Pathol.</i> 21(1): 1-34 (1989).	
	11	Shima, et al. "The Mouse Gene for Vascular Endothelial Growth Factor." <i>The Journal of Biological Chemistry</i> . 271(7): 3877-3883 (1996).	
	12	Tischer, et al. "The Human Gene for Vascular Endothelial Growth Factor." <i>The Journal of Biological Chemistry</i> . 266(18): 11947-11954 (1991).	
	13	Willet, et al. "Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer." <i>Nature Medicine</i> . 10(2): 145-147 (2004).	

2000945 SMA101805

Examiner Signature 	Date Considered 11/16/05
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.